Koyfin Home > Directory > Health Care > Arbutus Biopharma Cp

Arbutus Biopharma Cp Price Chart ABUS

Historical daily share price chart and data for Arbutus Biopharma Cp since 2007 adjusted for splits and dividends. The latest closing price for Arbutus Biopharma Cp as of February 19, 2020 is $3.27.
  • In 2020 the stock opened at $2.78 and closed at $3.27 for a gain of 15% YTD.
  • In 2019 the stock opened at $3.74 and closed at $2.78 for a loss of -35%.
  • In 2018 the stock opened at $5.00 and closed at $3.83 for a loss of -31%.
  • In 2017 the stock opened at $2.45 and closed at $5.05 for a gain of 51%.
View Chart On Koyfin

Arbutus Biopharma Cp Summary

Stock Symbol: ABUS

Arbutus Biopharma Cp Company Info

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
58.76 %
30D Volatility
Hedge Fund Held
0.48 %

Last 10 Days of ABUS Prices